Qeen.ai has raised $10 million to scale its platform, which provides autonomous AI agents for e-commerce businesses in the ...

Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google (GOOGL) executive.

The CEO of Google Mind has suggested clinical trials of the first drugs designed with the help of AI could begin this year.

Isomorphic was spun out of Google’s AI research arm Google DeepMind in 2021, but remains a wholly owned subsidiary of its parent company, Alphabet. The start-up’s potential has attracted big ...

Google DeepMind spinoff Isomorphic Labs expects testing on its first AI-designed drugs to begin this year, as tech startups ...

On its own, Google Fit is a basic fitness app. However, it also acts as a hub for any fitness or health data gathered from popular apps and fitness trackers. Let’s say you use a Nest Hub for ...

Murati has poached roughly 10 researchers and engineers in total so far from competitors including OpenAI, Character AI, and Google DeepMind. Her startup is still in its early stages—it doesn ...

The laboratory of the latest Nobel Prize winner in Chemistry David Baker, headed by researcher Susana Vázquez, talks about ‘democratizing’ the discovery of therapies ...

DeepMind, headquartered in London ... The company's commitment to improving global health through AI-driven innovation cements its place among Europe’s top AI startups. TwentyBN, based in Berlin, ...

Others, including Google DeepMind’s Demis Hassabis, say that several major breakthroughs are still needed to achieve AGI and this could take at least a decade. Running out of data to train AI models ...